Healthcare & Life Sciences
MoglingBio
Germany
seed
seed
Stage
1
Investors
About
MoglingBio develops pharmacological methods to rejuvenate aged hematopoietic stem cells by normalizing CDC42 protein activity to restore their structure and function, aiming to improve blood and immune cell production and treat age-related blood and immune dysfunction.
Explore MoglingBio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.